Collectively, we provided solid evidence, through patient tissues and cell and animal models, that FER1L4 promoted liver cancer by downregulating miR-106a-5p and miR-372-5p, thus leading to an increased expression of E2F1 and NF-κB pathway. Here, FER1L4 is linked to liver cancer.